Cargando…
Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Autores principales: | Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Borg, Danielle J., Flemming, Nicole B., Harvie, Ben M., Kinneally, Toni L., Yeh, Shang-Ming, McCarthy, Domenica A., Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha, Forbes, Josephine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936511/ https://www.ncbi.nlm.nih.gov/pubmed/27389496 http://dx.doi.org/10.1038/srep28124 |
Ejemplares similares
-
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
por: Gallo, Linda A., et al.
Publicado: (2016) -
Cardioprotective effects of short-term empagliflozin treatment in db/db mice
por: Radlinger, Bernhard, et al.
Publicado: (2020) -
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020) -
Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice
por: Klimontov, Vadim V, et al.
Publicado: (2020) -
Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
por: Tu, Yimin, et al.
Publicado: (2022)